Update Course Rewind: Staging and Management of Neuroblastoma 2022
With Dr. Dr. Paul Yasurjak · StayCurrentMD
Part of
Neuroblastoma 26 items
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
Video
Social Determinants of Health Influence on Survival in Wilms Tumor, Neuroblastoma, and Hepatoblastoma
1 min · Published Jan 2026
Video
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report
59 s · Published Mar 2026
Video
Image-guided core-needle or surgical biopsy for neuroblastoma diagnosis in children
54 s · Published Feb 2024
Video
Neuroblastoma: Update Course 2014
CCHMC Pediatric Surgery · 25 min · Published Nov 2018
Video
Dominique Simons, MSc - Best of the Best in Pediatric Surgery 2024
Dr. Todd Ponsky · 7 min · Published Feb 2024
Video
Dr. Yujie Ma - Best of the Best in Pediatric Surgery 2025
Dr. Todd Ponsky · 8 min · Published Mar 2025
Only a few other public items share this expert — go deeper there →
Video
Pediatric Surgical Oncology Research Collaborative (PSORC): Studying Rare Pediatric Tumors
56 s · Published May 2026
Video
Update Course Rewind 2025: Hirschsprung + ARM: Rare but Real
1 min · Published May 2026
Video
Update Course Rewind 2025: Hirschsprung + ARM: Rare but Real
1 min · Published May 2026
Video
Pooling Patients to Study Rare Pediatric Tumors: An Introduction to PSORC
56 s · Published May 2026
Video
The fetal frontier: A review of current and emerging fetal therapies for genetic diseases
44 s · Published May 2026
Video
Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients
1 min · Published May 2026
What the experts said
The presented case is a 16-month-old with a right adrenal mass measuring 8 centimeters
Biopsy showed favorable cell neuroblastoma biology with no MYCN amplification but with segmental chromosomal abnormalities
The Children's Oncology Group neuroblastoma classification tree is constantly changing as new information is added
Based on the 2021 COG classification, the presented tumor would be classified as higher risk
COG reviewed patients enrolled in trials between 2007 and 2017
The presence of segmental chromosomal aberrations such as loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes
The updated schema classifies tumors as high risk when there is no MYCN amplification but segmental chromosomal abnormalities are present